The industrial partner Readycell, together with the Medical Department from Leitat Technological Center and public research institution Vall d’Hebron Institut de Recerca (VHIR) have received funding for the development of its public-private research collaboration project 3DLIVER: “Innovative Human-Derived 3D Liver Models for Drug Toxicity Testing and Discovery”.
The 3DLIVER project has been awarded the competitive grant “Proyectos en Colaboración Público-Privada 2021” from the Spanish Ministry of Science and Innovation (Ministerio de Ciencia e Innovación) through its funding agency Agencia Estatal de Investigación (AEI).
The main objective of this project is to develop novel 3D in vitro tools derived from the human liver, relevant to the discovery and preclinical phases of drug development.
The project consortium involves leading partners in different expertise areas to ensure the success of this innovative proposal. The Donation and Transplant Coordination Department as well as both the Paediatric Hepatology and Liver Transplantation, and the Hepatobiliopancreatic Surgery and Transplants Departments from Vall d’Hebron University Hospital, and their respective research groups (Organ, tissue and cell donation and transplantation and HBPI Transplant Surgery) from Vall d’Hebron Institute of Research (VHIR) – Vall d’Hebron Institut de Recerca will coordinate and obtain liver tissue from the organs donated and discarded for transplantation.
The Leitat Medical Department of the Leitat Technological Center will be responsible of optimizing the isolation, culture and banking of liver cells and generate spheroid and organoid banks. Finally, ReadyCell S.L., as the project coordinator, will also help transform these 3D models into ready-to-use in vitro tools that contribute to optimize the overall drug discovery process.
ReadyCell is currently involved in a total of four projects, both public and private.
